<DOC>
	<DOC>NCT01439880</DOC>
	<brief_summary>The primary clinical hypothesis is that long-term exposure of evolocumab (AMG 145) will be safe and well tolerated in subjects with hypercholesterolemia.</brief_summary>
	<brief_title>Open Label Study of Long Term Evaluation Against LDL-C Trial</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Complete a qualifying evolocumab (AMG 145) parent study protocol Experienced a treatmentrelated serious adverse event that led to IP discontinuation in the parent study Have an unstable medical condition, in the judgment of the investigator Known sensitivity to any of the products to be administered during dosing Currently enrolled in another investigational device or drug study (excluding evolocumab (AMG 145) parent study), or less than 30 days since ending another investigational device or drug study(s),or receiving other investigational agent(s)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>High cholesterol</keyword>
	<keyword>Raised cholesterol</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>Elevated Cholesterol</keyword>
</DOC>